Invivyd
Develops antibody medicines for prevention and treatment of serious viral diseases, including COVID-19
Highlights
- New on EvolcAdded 2026-11-13
Recent signals
What changed at Invivyd in the last 6 months, newest first. Each line links to its public source.
- 13 Nov 2026 Leadership hire · Hiring Vice President, Associate General Counsel, Infectious Disease… (New Haven) job-boards.greenhouse.io
- 30 Sep 2026 Leadership hire · Hiring Senior Director, Strategic IDNs and Health System Access job-boards.greenhouse.io
About Invivyd
Invivyd is a biopharmaceutical company developing monoclonal antibody candidates for the prevention and treatment of serious viral infectious diseases. Its approach combines viral surveillance and predictive modeling with antibody engineering.
The company has a commercial product, PEMGARDA, authorized by the FDA for emergency use under specified conditions, and a pipeline spanning COVID-19, influenza and other indications. Its commercial and research activities include partnerships with biopharmaceutical companies, universities and academic medical centers.
Invivyd is headquartered in New Haven, Connecticut, and has open roles across sales, market access, marketing and legal functions in the United States.
Product: Monoclonal antibody medicines and candidates for prevention or treatment of serious viral infectious diseases.
Jobs at Invivyd
Open roles at Invivyd in the Americas (2)
United States 2. From Invivyd's careers page or applicant tracking system; each role links to the employer.
- Vice President, Associate General Counsel, Infectious Disease Franchise · New Haven, United States
- Senior Director, Strategic IDNs and Health System Access · United States
More biotech & pharma companies
Isbscience
Biomedical research institute studying complex biological systems to improve human health and disease treatmentNew on EvolcJade Biosciences
Developing monoclonal antibody therapies for patients with serious autoimmune diseasesNew on EvolcJsrglobal
Contract development and cGMP manufacturing of biologics, plus analytical testing, for biopharmaceutical companiesRemote-friendlySalary transparentKardigan
Develops targeted cardiovascular medicines for patients with heart and vascular diseasesKura Oncology
Develops targeted precision cancer therapies for head and neck cancer, lung cancer and acute leukemiasNew on EvolcMadrigalpharma
Develops MASH medicines for patients and healthcare systems in the United States and EuropeNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- FastlyHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-served-by
- Response headerx-served-by
- Response headerx-served-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Monitoring
- New RelicMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinitialization/configuration expression
- Integration code on pageinitialization/configuration expression
- Integration code on pageinitialization/configuration expression
Privacy & consent
- OneTrustHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- GreenhouseMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.